Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A **synthetic** monomeric, cyclic **B-chain** peptide ~~**analogue of a B-chain**~~ of a relaxin superfamily member protein which binds to a biological target of the relaxin superfamily protein, and modulates an activity of the biological target, wherein the relaxin superfamily protein is selected from ~~**insulin, IGF-I, IGF-II,**~~ relaxin 1, relaxin 2, relaxin 3, INSL3, INSL4, INSL5 and INSL6, **which relaxin superfamily protein corresponds to SEQ ID NO: 1, 2, 3, 7, 8, 9, 10, respectively,** the biological target being selected from insulin receptors, IGFR-I, IGFR-II, LGR7 and LGR8 and wherein the ~~**analogue**~~ **cyclic peptide has an intrapeptide cyclization modification** ~~**is produced by modification of a turn or loop moiety**~~ **to produce a cross-link between a first amino acid within a range of amino acid positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of each of said peptide sequences,** ~~**the B-chain of the relaxin superfamily protein, the modification involving selection of at least a first and a second amino acid residue with an alpha-helix or beta-strand carbon separation distance of less than six angstroms and cross-linking the first and second amino acids,**~~ wherein the cross-link conformationally constrains the ~~**analogue**~~ **peptide, and wherein said intrapeptide cyclization is via the formation of a covalent bond between the side chains of said first and second amino acids or a disulfide bond between two cysteine residues, wherein said two cysteine residues are substituted for said first and said second amino acids, or a thioether bond between a substituted cysteine residue at said first or said second amino acid and a halogenated amino acid residue at the other position, either directly or via a spacer group.**

2. (canceled)

3. (currently amended) The **peptide** ~~**analogue**~~ according to claim 1, wherein the **peptide** ~~**analogue**~~ is an INSL3 B-chain ~~**analogue**~~ modified from a sequence set forth in SEQ ID NO:7.

4. (withdrawn – currently amended) The **peptide** ~~**analogue**~~ according to claim 3, wherein the INSL3 **peptide** ~~**analogue**~~ is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequence set forth in SEQ ID NO:7.

5.-6. (canceled)

7. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 1, which is a relaxin **peptide** ~~**analogue**~~ modified from a relaxin-1, relaxin-2, or relaxin-3 B-chain sequence set forth in SEQ ID NOs: 1, 2 and 3, respectively.

8. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 7, wherein the relaxin **peptide** ~~**analogue**~~ is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequence set forth in SEQ ID NO:2.

9. (canceled)

10. (withdrawn – currently amended) The **peptide** ~~**analogue**~~ according to claim 1, wherein the first and/or second amino acids are substituted with alternative amino acids suitable for cross-linking.

11. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 10 wherein at least one of the alternative amino acids is a cysteine residue.

12. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 11 wherein both of the alternative amino acid residues are cysteine residues.

13. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 12 wherein the **peptide** ~~**analogue**~~ is cross-linked by oxidizing the cysteine residues to form a disulfide bond between the cysteine residues.

14. (withdrawn - currently amended) **[[An]] A peptide** ~~**analogue**~~ according to claim 1, wherein one or more amino acids within the ~~**INSL3**~~ INSL or relaxin peptide ~~**analogue**~~ sequence, other than the cross-linked first and second amino acids, is substituted to modify one or more biological activities of the **peptide** ~~**analogue**~~.

15. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 1 wherein the biological target of the **peptide** ~~**analogue**~~ is LGR7 and/or LGR8.

16. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 15, wherein activity of the biological target is initiated, up-regulated, down-regulated or otherwise blocked.

17. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ of claim 1, wherein the **peptide** ~~**analogue**~~ is conjugated to an A-chain of a relaxin superfamily protein.

18. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 17, wherein the A-chain of the relaxin superfamily protein is derived from the relaxin superfamily protein from which the B chain **peptide** ~~**analogue**~~ is derived.

19. (withdrawn- currently amended) The **peptide** ~~**analogue**~~ according to claim 1, wherein the **peptide** ~~**analogue**~~ is conjugated to a reporter group.

20. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according **to** **[[the]]** claim 19, wherein the reporter group is a radiolabel.

21. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 19, wherein the reporter group is a fluorescent label.

22. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 19, wherein the reporter group is an enzyme.

23. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 19, wherein the reporter group is a carrier.

24.-31. (canceled)

32. (currently amended) A pharmaceutical composition including one or more of the **peptides** ~~**analogues**~~ as claimed in claim 1, or pharmaceutically acceptable salts thereof.

33. (original) The pharmaceutical compositions according to claim 32, further comprising at least one pharmaceutically acceptable carrier or diluent.

34.-49 (canceled)

50. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 1, ~~**wherein the analogue is an INSL3 analogue**~~ with the **following** sequence and structure:

TPCMREKLSGHHFVRALVRVSGGPCWS

51. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 1, ~~**wherein the analogue is an INSL3 analogue**~~ with the **following** sequence and structure:

TP**C**MREKLSGRHFVRALVRVSGGP**C**WS

52. (withdrawn - currently amended) The **peptide** ~~**analogue**~~ according to claim 1, ~~**wherein the analogue is a relaxin analogue**~~ with the **following** sequence and structure:

S**C**MEEVIKLSGRELVRAQIAISG**C**S